--- title: "由於超級細菌治療的後期試驗取得進展，Armata Pharmaceuticals 的股票大幅上漲" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/293234406.md" description: "Armata Pharmaceuticals 的股價在宣佈其 AP-SA02 的第三階段試驗關鍵里程碑後上漲了 18%。該療法是一種針對超級細菌（如 MRSA）的噬菌體療法。公司已向 FDA 提交最終測試計劃，並在其洛杉磯設施完成了工程運行。Armata 從美國國防部獲得了額外的 250 萬美元資金，使總融資達到 2870 萬美元。首席執行官 Deborah Birx 強調，推進第三階段研究仍然是首要任務" datetime: "2026-07-20T15:29:45.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293234406.md) - [en](https://longbridge.com/en/news/293234406.md) - [zh-HK](https://longbridge.com/zh-HK/news/293234406.md) generator: "portal-rs" --- # 由於超級細菌治療的後期試驗取得進展，Armata Pharmaceuticals 的股票大幅上漲 By Anvee Bhutani Armata Pharmaceuticals shares rose Monday after the company said it took a major step toward the launch of a late-stage trial for its experimental superbug treatment, AP-SA02. In morning trading, Armata shares were up 18% at $5.31. The biotechnology company said it achieved key clinical, regulatory and manufacturing milestones supporting the planned launch of a Phase 3 trial of the treatment, and submitted its final testing plans to the U.S. Food and Drug Administration. The bacteriophage therapy targets so-called superbugs such as MRSA. The company also said it completed four engineering runs of AP-SA02 at its Los Angeles facility. Production of clinical trial material will be the next manufacturing step ahead of the planned Phase 3 study. Armata said it remains on track to begin the pivotal Phase 3 superiority study in the second half of 2026. The trial will evaluate AP-SA02 as an add-on treatment for severe Staphylococcus aureus bacteremia, including MRSA, and is intended to support a future biologics license application. Separately, the company said it recently received an additional $2.5 million in funding from the U.S. Defense Department, bringing total funding under the award to $28.7 million. The new funding will support preparations for the Phase 3 trial, while Armata said it is also pursuing additional financing sources to fund the study. Chief Executive Deborah Birx said advancing AP-SA02 into Phase 3 remains the company's top priority. Armata also promoted David House to chief financial officer from senior vice president of finance and principal financial officer. Write to Anvee Bhutani at anvee.bhutani@wsj.com (END) Dow Jones Newswires July 20, 2026 11:19 ET (15:19 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. ### 相關股票 - [ARMP.US](https://longbridge.com/zh-HK/quote/ARMP.US.md) ## 相關資訊與研究 - [Armata Pharmaceuticals 表示，吸入式噬菌體候選藥物 AP-PA02 已在囊性纖維化和支氣管擴張患者中完成了第二階段臨牀試驗](https://longbridge.com/zh-HK/news/297902417.md) - [分析師維持對 Armata 的買入評級，因為 AP-SA02 即將進入第三階段，受到監管利好因素的支持，並設定了基於 DCF 的 20 美元目標價](https://longbridge.com/zh-HK/news/297360426.md) - [Aptevo 報告稱，Mipletamig 三聯療法在難治性 TP53 突變的初治急性髓性白血病中臨牀獲益率達到 93% | APVO 股票新聞](https://longbridge.com/zh-HK/news/297911849.md) - [據《華爾街日報》報道，諾華製藥在出現死亡病例後暫停自身免疫細胞療法研究](https://longbridge.com/zh-HK/news/297596287.md) - [考拉試驗首次為患者注射新型 KMA 靶向 CAR-T 細胞療法](https://longbridge.com/zh-HK/news/298021066.md) --- > **免責聲明: 本文僅供參考，不構成任何投資建議。**